OCUTF (Ocumension Therapeutics) Other Operating Expense: $23.0 Mil (TTM As of Dec. 2025)


OCUTF Ocumension Therapeutics OCUTF
52 GF Score
Price $0.70
GF Value $2.82
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Ocumension Therapeutics Other Operating Expense?

Ocumension Therapeutics OCUTF 52 Other Operating Expense is $23.0 Mil as of Dec. 2025. GuruFocus rates OCUTF with a GF Score™ of 52/100 and a GF Value™ of $2.82 (Possible Value Trap). The stock has 5 warning signs investors should review.

Ocumension Therapeutics's Other Operating Expense for the six months ended in Dec. 2025 was $12.9 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was $23.0 Mil.

Ocumension Therapeutics's quarterly Other Operating Expense declined from Dec. 2024 ($10.2 Mil) to Jun. 2025 ($10.0 Mil) but then increased from Jun. 2025 ($10.0 Mil) to Dec. 2025 ($12.9 Mil).

Ocumension Therapeutics's annual Other Operating Expense declined from Dec. 2023 ($20.0 Mil) to Dec. 2024 ($19.8 Mil) but then increased from Dec. 2024 ($19.8 Mil) to Dec. 2025 ($23.2 Mil).

Ocumension Therapeutics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Ocumension Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocumension Therapeutics Other Operating Expense Chart

Ocumension Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial -0.06 19.60 20.02 19.81 23.17

Ocumension Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.73 9.67 10.18 10.04 12.93
OCUTF
52GF Score
Ocumension Therapeutics OCUTF
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ocumension Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $23.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $23.0 Mil mean?
Ocumension Therapeutics (OCUTF) has a Other Operating Expense of $23.0 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Ocumension Therapeutics and its competitors.
Is Ocumension Therapeutics' Other Operating Expense too high?
Ocumension Therapeutics' current Other Operating Expense is $23.0 Mil. Overall, Ocumension Therapeutics has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ocumension Therapeutics' Other Operating Expense compare to VRTX and REGN?
Ocumension Therapeutics' Other Operating Expense of $23.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Ocumension Therapeutics and its competitors. Ocumension Therapeutics's current Other Operating Expense is $23.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocumension Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ocumension Therapeutics (OCUTF) is currently considered Possible Value Trap. The stock's GF Value™ is $2.82, compared to a current price of $0.70 — trading 75.2% below its estimated fair value. The current Other Operating Expense is $23.0 Mil. Ocumension Therapeutics' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Ocumension Therapeutics (OCUTF), the current Other Operating Expense is $23.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ocumension Therapeutics (OCUTF) Overvalued in 2026?

Based on GuruFocus' analysis, Ocumension Therapeutics stock appears to be undervalued. The current stock price of $0.70 is trading 75.2% below its estimated GF Value™ of $2.82. GuruFocus considers Ocumension Therapeutics to be Possible Value Trap.

Key valuation signals for OCUTF:

  • Other Operating Expense: $23.0 Mil
  • GF Value™: $2.82 vs. price of $0.70 (75.2% below fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the OCUTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ocumension Therapeutics Business Description

Other Exchanges 01477:Hong Kong5DG:Germany
Address No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
52GF Score

Get the complete analysis for OCUTF

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price
$2.82
GF Value